Year All20232022202120202019201820172016201520142013201220112009 May 16, 2023 REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio May 08, 2023 REGENXBIO to Participate in Upcoming Investor Conferences May 03, 2023 REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights May 02, 2023 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting Apr 26, 2023 REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights Apr 18, 2023 REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Apr 11, 2023 REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
May 16, 2023 REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio
May 03, 2023 REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
May 02, 2023 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting
Apr 26, 2023 REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights
Apr 18, 2023 REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Apr 11, 2023 REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
